Furthermore, these results suggest that targeting STAT3 using small-molecule inhibitors such as TTI-101 deserves consideration as a new approach to the treatment of IBD, particularly in patients refractory to current therapies. The gene discussed is STAT3; the disease is inflammatory bowel disease.